F-box and leucine rich repeat protein 21, pseudogeneGenealiases: FBL3B · FBXL21 · FBXL3B · FBXL3P · Fbl21
Q-omics provides the consensus-scored FBXL21P profile across patient tissues and cancer cell-line models. FBXL21P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FBXL21P is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FBXL21P RNA expression shows 13,630 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KICH, and TGCT as cancer lineages where FBXL21P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL21P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL21P survival associations across molecular data types. FBXL21P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL21P RNA expression–survival associations across cancer types. High FBXL21P expression shows unfavorable associations in UCEC, CHOL and LUAD, but favorable associations in KIRP, THCA and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FBXL21P RNA expression.
This table summarizes FBXL21P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FBXL21P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL21P shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, THCA, BRCA and LUSC. The KICH box plot shows higher FBXL21P RNA expression in normal versus tumor tissue (log2 FC = −1.827, t-test p < 0.001).
This table shows molecular features associated with FBXL21P in patient tissues and cancer cell lines. In patient samples, FBXL21P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL21P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
